Methenamine Hippurate Dosing for UTI Prophylaxis
For UTI prophylaxis, methenamine hippurate should be dosed at 1 g twice daily (morning and night) in adults and children over 12 years of age, and 0.5-1 g twice daily in children 6-12 years of age. 1
Adult Dosing
The standard prophylactic dose is 1 g twice daily (morning and night), as confirmed by both FDA labeling 1 and clinical trial evidence 2, 3. This dosing regimen was used in the landmark ALTAR trial, which demonstrated non-inferiority to antibiotic prophylaxis for preventing recurrent UTIs in women 3.
Pediatric Dosing
- Children >12 years: 1 g twice daily 1
- Children 6-12 years: 0.5-1 g twice daily 1
- Children <6 years: Insufficient data for clear dosing recommendations
The FDA labeling specifically approves methenamine for patients 12 years and older 4, though some guidelines reference use in younger children with appropriate dose adjustments 1.
Critical Dosing Considerations
Urinary pH Management
Maintain urinary pH below 6.0 for optimal efficacy 2. The antibacterial activity depends on conversion of methenamine to formaldehyde, which requires acidic urine 2. However, the optimal method to achieve low urinary pH remains unclear 2.
- Ascorbic acid up to 4 g/day shows minimal effect on urinary pH 2
- Doses as high as 12 g/day of ascorbic acid or more frequent administration may be needed 2
- The evidence notes that concentrations achieved with 12-hour dosing intervals may be suboptimal 2
Common Pitfall
Do not use methenamine for long-term catheter-associated UTI prevention. Guidelines explicitly recommend against routine use in patients with long-term intermittent or indwelling catheters (Grade A recommendation) 2. The drug showed no benefit in a 305-patient trial of catheterized patients with neurogenic bladder 2.
Clinical Context for Use
Methenamine is most appropriate for:
- Postmenopausal women with recurrent UTIs as an antimicrobial-sparing alternative 4, 3
- Patients with intact bladder anatomy (not catheterized) 4
- Short-term post-surgical prophylaxis (≤1 week after gynecologic procedures) 2
The 2024 WikiGuidelines consensus provides a clear recommendation for methenamine as an appealing antimicrobial-sparing intervention, particularly valuable given rising antibiotic resistance 4. The ALTAR trial demonstrated that while methenamine resulted in 0.49 more UTIs per person-year compared to antibiotics, this difference did not exceed the predefined non-inferiority margin, and importantly, antibiotic resistance was significantly lower in the methenamine group (56% vs 72%) 3.
Duration of Therapy
Treatment duration should be at least 6-12 months based on clinical trial evidence 3, 5. The ALTAR trial used 12 months of treatment 3, while older studies demonstrated efficacy with 6-month courses 5, 6. Monitor efficacy through repeated urine cultures 1.